Downloading...
Download

ARWR

$ARWR + Stocks I'm looking to get into immediately.All long positions for the following: Markups as requested. I can only do 10 posts in a 24 hour period which is a limiting factor. I'm not usually bogged down with requests. I'm not saying I want to be bogged down, but I kind of like doing these. They are like crossword puzzles or sudoku for me. Except I suck crosswords and sudoku. They are like a fun puzzle for me is a better phrasing. I actually don't enjoy puzzles though. Idk maybe you get what I'm going for. --------- AAL ADP ARWR BEAM CNNE ESRT GMBL GRUB TCOM THS VSAT
NASDAQ:ARWRLong
by emehoke
2
Arrowhead Pharmaceuticals $ARWR $ARWR let me be honest this is up 6000% since Dec 2016 & they still don't have phase 3 yet which hold a variety of uncertainties. Anyhow this has been one of the best performing stocks over the past couple years, and I am still a bit hesitant to go against it. I might be early but I still want to get this out as it could be really great opportunity to play the downside. Personally I would not want to be a buy up here as were hitting major resistance and a choppy trading zone. The monthly chart looks exhausted and ready to take a break. We all know biotechs are crazy, they can run & run and run then on the flip of a dime they crash much harder & faster than they came up. After having this non-stop run over the past 3 year, I would not be surprised to see a pull-back in the near future even though they had a great 10Q & have plenty of cash from the Janssen deal. Here are some important notes from the 10Q www.sec.gov We expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all. We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability. We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts. Janssen, and the premium JJDC paid on the Company’s common stock during the period. With this being said I am looking at 6/19/20 $50 Puts & for more near-term i'm looking at 3/20/20 $50 puts GLTA
NASDAQ:ARWRShort
by AaronX
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it. Increased quarterly earnings growth. Low floater Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83 Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
N
by alipipefitter
1